6-K
Report of Foreign Issuer
Evaxion A/S Filed Acc 0001171843-26-007220
New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01
- Detection of neoantigen-specific T cells directly ex vivo indicates strong EVX-01-induced immune responses
From the SEC's structured data for this filing
Loading f6k_110626.htm…